Academic Journals Database
Disseminating quality controlled scientific knowledge

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma

ADD TO MY LIST
 
Author(s): Francesca Cainelli | Alfredo Vallone

Journal: Biologics : Targets & Therapy
ISSN 1177-5475

Volume: 2009;
Issue: default;
Start page: 385;
Date: 2009;
Original page

ABSTRACT
Francesca Cainelli1, Alfredo Vallone21Department of Internal Medicine, School of Medicine, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana; 2Infectious Diseases Unit, Annunziata Hospital, Cosenza, ItalyAbstract: Kaposi’s sarcoma is a vascular tumor linked to the presence of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8) and the incidence of which has increased considerably the world over after the onset of the human immunodeficiency virus (HIV) pandemic. Antiretroviral therapy combined with cytotoxic agents has been established as the treatment of choice in the past 10 years. Among chemotherapeutic agents, pegylated liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi’s sarcoma in Western countries. The drug in this formulation localizes better to the tumor and has higher efficacy. Skin toxicity, mucositis, and leukopenia/neutropenia are the main side effects. Hepatotoxicity and mild cardiotoxicity are observed less frequently. Pegylated liposomal doxorubicin impacts favorably on quality of life. Although cost effective in Western countries, the drug is less so in developing countries.Keywords: pegylated liposomal doxorubicin, Kaposi’s sarcoma, HIV infection
Save time & money - Smart Internet Solutions     

Tango Rapperswil
Tango Rapperswil